Especially with growing knowledge about tumor immune microenvironment (TIME), as described later in this introduction, another promising therapy option was the treatment with immune checkpoint inhibitors (ICI), with PD-L1 and PD-1 as the most prominent ICIs. This evidence concerns the gene CD274 and neoplasm.